CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6226 result(s)

indacaterol /mometasone furoate (Atectura Breezhaler)

Last Updated: November 26, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: indacaterol /mometasone furoate
Indications: Indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. Atectura Breezhaler should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS.

  • Brand Name: Atectura Breezhaler
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0646-000
  • Project Status: Active
  • Submission Type: Initial

Indacaterol glycopyrronium mometasone furoate (Enerzair Breezhaler)

Last Updated: November 26, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: indacaterol glycopyrronium mometasone furoate
Indications: Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.

  • Brand Name: Enerzair Breezhaler
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0645-000
  • Project Status: Active
  • Submission Type: Initial

liraglutide (Saxenda)

Last Updated: November 26, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Pending
  • Submission Type: Initial

patiromer (Veltassa)

Last Updated: November 25, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: patiromer
Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

  • Brand Name: Veltassa
  • Manufacturer: Otsuka Canada Pharmaceuticals Inc.
  • Project Number: SR0665-000
  • Project Status: Active
  • Submission Type: Initial